05-02-2013

Data from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin (BCG) vaccine, the currently licensed and widely used ...

more

19-09-2012

A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium ...

more

16-12-2011

A research team from the National University of Singapore (NUS) Singapore Lipidomics Incubator (SLING) is collaborating with the Foundation for Innovative New Diagnostics (FIND) to identify novel target molecules to be employed as biomarkers for the detection of active tuberculosis (TB). The ...

more

21-02-2011

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight ...

more

13-09-2010

Tuberculosis, or TB, is a dreaded contagious disease of the lungs and other organs. The causative agent, Mycobacterium tuberculosis (or M. tuberculosis ), infects roughly a third of the world's population and one-in-ten to one-in-twenty of the infected population becomes sick or infectious at ...

more

25-08-2010

An unlikely effort is underway to lift the veil of nearly-total secrecy that has surrounded the process of developing new prescription drugs for the last century, scientists said at the 240th National Meeting of the American Chemical Society (ACS). The upheaval in traditional practice would ...

more

02-07-2010

Sanofi-aventis announced that the European Commission has granted Orphan Drug status for rifapentine for the treatment of tuberculosis (TB). Rifapentine is an antibiotic member of the rifamycin class, with a higher inhibitory activity against Mycobacterium tuberculosis and a longer half-life ...

more

Findings further understanding of how pathogen survives

17-05-2010

Scientists looking for new ways to fight tuberculosis (TB) have their sights set on a structure essential to the bacterium's survival. Disabling this structure could kill the microbes in the infected host and thwart TB infections. In a study in EMBO Journal scientists from the U.S. Department ...

more

14-05-2010

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. The cause of tuberculosis is Mycobacterium tuberculosis (Mtb), a slow-growing aerobic ...

more

26-04-2010

Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents. Tonge presented these results at the American Society for ...

more